Q1 2026 Operating Profit Swings to Black, Revenue Up 10.7%

Consolidated Q1 2026 revenue: 40,031 million KRW, up 10.7% YoY and 6.6% QoQ
Operating profit of 839 million KRW, swinging to black from -2,016 million KRW in Q4 2025 and -394 million KRW in Q1 2025
Net profit of 275 million KRW, swinging to black from -6,248 million KRW in Q4 2025 and -208 million KRW in Q1 2025
Standalone revenue: 40,031 million KRW, operating profit: 1,180 million KRW, net profit: 650 million KRW
Preliminary figures under K-IFRS consolidated basis, subject to change after external audit

04-29-2026
Consolidated Financial Statements Basis Operating (Provisional) Results (Fair Disclosure)
Company: Hanall Biopharma (009420)
Submission: Hanall Biopharma Co., Ltd.
Under KRX KOSPI Market Division